menu
    • menu
    [{"orgOrder":0,"company":"METiS Therapeutics","sponsor":"Evopoint Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"METiS Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"METiS Therapeutics \/ Evopoint Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"METiS Therapeutics \/ Evopoint Biosciences"},{"orgOrder":0,"company":"METiS Therapeutics","sponsor":"METiS Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"MTS105","moa":"CD3\/GP3","graph1":"Oncology","graph2":"Phase I","graph3":"METiS Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"METiS Therapeutics \/ METiS Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"METiS Therapeutics \/ METiS Therapeutics"},{"orgOrder":0,"company":"METiS Therapeutics","sponsor":"Voronoi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"METiS Therapeutics","amount2":0.47999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.47999999999999998,"dosageForm":"Undisclosed","sponsorNew":"METiS Therapeutics \/ METiS Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"METiS Therapeutics \/ METiS Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by METiS Therapeutics

    Menu

    METiS Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            METiS Therapeutics

                            U.S.A arrow
                            NASP
                            Not Confirmed

                            METiS Therapeutics

                            U.S.A arrow
                            NASP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTS105

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Shen Lin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mts105 for Advanced Hepatocellular Carcinoma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 14, 2024

                            Lead Product(s) : MTS105

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Shen Lin

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            METiS Therapeutics

                            U.S.A arrow
                            NASP
                            Not Confirmed

                            METiS Therapeutics

                            U.S.A arrow
                            NASP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Evopoint Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            METiS Announces License Agreement with Evopoint Biosciences

                            Details : Under the terms of the collaboration, METiS will receive an exclusive, worldwide, royalty-bearing license to develop and commercialize Evopoint’s SOS1 inhibitor program, a key regulatory protein/node in the RAS/MAPK pathway.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Evopoint Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            METiS Therapeutics

                            U.S.A arrow
                            NASP
                            Not Confirmed

                            METiS Therapeutics

                            U.S.A arrow
                            NASP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Voronoi

                            Deal Size : $482.2 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            METiS Announces Pan-RAF Inhibitor License Agreement with Voronoi

                            Details : Under the terms of this license agreement, METiS will receive exclusive license to develop and commercialize Voronoi’s pan-RAF inhibitor program worldwide.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $1.7 million

                            September 13, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Voronoi

                            Deal Size : $482.2 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth